Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment.

Abstract

Olanzapine is the one of first line antipsychotic drug for schizophrenia and other serious mental illness. However, it is associated with troublesome metabolic side-effects, particularly body weight gain and obesity. The antagonistic affinity to histamine H1 receptors (H1R) of antipsychotic drugs has been identified as one of the main contributors to weight gain/obesity side-effects. Our previous study showed that a short term (2 weeks) combination treatment of betahistine (an H1R agonist and H3R antagonist) and olanzapine (O+B) reduced (-45%) body weight gain induced by olanzapine in drug-naïve rats. A key issue is that clinical patients suffering with schizophrenia, bipolar disease and other mental disorders often face chronic, even life-time, antipsychotic treatment, in which they have often had previous antipsychotic exposure. Therefore, we investigated the effects of chronic O+B co-treatment in controlling body weight in female rats with chronic and repeated exposure of olanzapine. The results showed that co-administration of olanzapine (3 mg/kg, t.i.d.) and betahistine (9.6 mg/kg, t.i.d.) significantly reduced (-51.4%) weight gain induced by olanzapine. Co-treatment of O+B also led to a decrease in feeding efficiency, liver and fat mass. Consistently, the olanzapine-only treatment increased hypothalamic H1R protein levels, as well as hypothalamic pAMPKα, AMPKα and NPY protein levels, while reducing the hypothalamic POMC, and UCP1 and PGC-1α protein levels in brown adipose tissue (BAT). The olanzapine induced changes in hypothalamic H1R, pAMPKα, BAT UCP1 and PGC-1α could be reversed by co-treatment of O+B. These results supported further clinical trials to test the effectiveness of co-treatment of O+B for controlling weight gain/obesity side-effects in schizophrenia with chronic antipsychotic treatment.

• Authors: Jiamei Lian, Xu-Feng Huang, Nagesh Pai, Chao Deng
• Journal: PloS one (PLoS One) Vol. 9 Issue 8 Pg. e104160 ( 2014) ISSN: 1932-6203 [Electronic] United States
• PMID: 25084453 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Benzodiazepines
• Olanzapine
• Betahistine

Topics

• Adipose Tissue, Brown (drug effects, metabolism)
• Adiposity (drug effects)
• Animals
• Benzodiazepines (adverse effects)
• Betahistine (pharmacology)
• Disease Models, Animal
• Feeding Behavior (drug effects)
• Female
• Hypothalamus (drug effects, metabolism)
• Lipid Droplets (drug effects)
• Liver (drug effects, pathology)
• Olanzapine
• Organ Size (drug effects)
• Rats, Sprague-Dawley
• Weight Gain (drug effects)